HAYA Therapeutics has raised USD 65 million in Series A Funding to accelerate the clinical development of its RNA-guided therapeutics platform, supporting its lead candidate HTX-001 aimed at treating heart failure.
Organizations Involved
Eli Lilly and Company
Company Description
HAYA Therapeutics is dedicated to treating heart failure through the discovery and development of innovative first-in-class RNA-based therapeutics, with a specific focus on long noncoding RNAs.
Market
Chronic and age-related diseases
Location
Switzerland
Coinvestors
Sofinnova Partners, Earlybird Venture Capital, Eli Lilly and Company, ATHOS, +ND Capital, Alexandria Venture Investments, LifeLink Ventures, Apollo Health Ventures, Longview Ventures, 4see ventures, BERNINA Bioinvest, Schroders Capital